Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT

Keith M. Stantz, Minsong Cao, Ning Cao, Yun Liang, Kathy Miller

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to quantify and model the longitudinal intra-tumor physiological response to a single dose of a monoclonal antibody specific to the VEGFR2 using dynamic contrast-enhanced CT. Material and Methods: Dynamic contrast-enhanced CT imaging was performed on athymic nude mice bearing xenograft VEGF-transfected MCF-7 tumors (MCF7 VEGF) to quantify intra-tumor physiology pre- and post-injection (days 2, 7, and 14) of a nonspecific (IgG1, controls) and specific (DC101, treated) monoclonal antibody targeting VEGFR2. Parametrical maps of tumor physiology-perfusion (F), permeability surface area (PS), fractional plasma (f p), and interstitial space (f is)-were obtained at four time points over a 2-week period. Results: A temporal multistage recovery process whereby a decoupling of the fractional change in physiological parameters (f p, F) was observed when comparing treated to control tumors: f p and perfusion decreased by a combined 27% (P<0.01) and 65% (P<0.01) on day 2, while only perfusion remained reduced by 46% (P<0.01) on day 7. Intra-tumor heterogeneity defined by the change in variance of perfusion decreased on days 2 and 7; no change in the variance of f p was observed. Analysis based on a mathematical model linking perfusion and vascular morphology indicates that a decrease in f p and perfusion was consistent with a reduction in blood vessel radius, followed by an increase in the vascular radius and tortuosity resulting in the decoupling of f p and perfusion before returning to control levels. Conclusion: Inhibiting VEGFR2 activity results in a temporal decoupling of physiological parameters, which can be explained by a combination of morphological changes influencing perfusion. Such a decoupling has the potential to significantly impact the delivery of pharmaceuticals and oxygen within solid tumors, critical factors in combined anti-angiogenic and radio- and chemotherapies.

Original languageEnglish
Pages (from-to)1183-1195
Number of pages13
JournalMolecular Imaging and Biology
Volume13
Issue number6
DOIs
StatePublished - Dec 2011

Fingerprint

Perfusion
Breast Neoplasms
Neoplasms
Blood Vessels
Nude Mice
Vascular Endothelial Growth Factor A
Injections
Heterografts
Permeability
Theoretical Models
Radiotherapy
Immunoglobulin G
Monoclonal Antibodies
Oxygen
Drug Therapy
Pharmaceutical Preparations

Keywords

  • DC101
  • DCE-CT
  • Fractional plasma volume
  • Heterogeneity
  • Perfusion

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT. / Stantz, Keith M.; Cao, Minsong; Cao, Ning; Liang, Yun; Miller, Kathy.

In: Molecular Imaging and Biology, Vol. 13, No. 6, 12.2011, p. 1183-1195.

Research output: Contribution to journalArticle

@article{f80320b1cd7f4ebba2e8c5df8106da78,
title = "Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT",
abstract = "Purpose: The purpose of this study was to quantify and model the longitudinal intra-tumor physiological response to a single dose of a monoclonal antibody specific to the VEGFR2 using dynamic contrast-enhanced CT. Material and Methods: Dynamic contrast-enhanced CT imaging was performed on athymic nude mice bearing xenograft VEGF-transfected MCF-7 tumors (MCF7 VEGF) to quantify intra-tumor physiology pre- and post-injection (days 2, 7, and 14) of a nonspecific (IgG1, controls) and specific (DC101, treated) monoclonal antibody targeting VEGFR2. Parametrical maps of tumor physiology-perfusion (F), permeability surface area (PS), fractional plasma (f p), and interstitial space (f is)-were obtained at four time points over a 2-week period. Results: A temporal multistage recovery process whereby a decoupling of the fractional change in physiological parameters (f p, F) was observed when comparing treated to control tumors: f p and perfusion decreased by a combined 27{\%} (P<0.01) and 65{\%} (P<0.01) on day 2, while only perfusion remained reduced by 46{\%} (P<0.01) on day 7. Intra-tumor heterogeneity defined by the change in variance of perfusion decreased on days 2 and 7; no change in the variance of f p was observed. Analysis based on a mathematical model linking perfusion and vascular morphology indicates that a decrease in f p and perfusion was consistent with a reduction in blood vessel radius, followed by an increase in the vascular radius and tortuosity resulting in the decoupling of f p and perfusion before returning to control levels. Conclusion: Inhibiting VEGFR2 activity results in a temporal decoupling of physiological parameters, which can be explained by a combination of morphological changes influencing perfusion. Such a decoupling has the potential to significantly impact the delivery of pharmaceuticals and oxygen within solid tumors, critical factors in combined anti-angiogenic and radio- and chemotherapies.",
keywords = "DC101, DCE-CT, Fractional plasma volume, Heterogeneity, Perfusion",
author = "Stantz, {Keith M.} and Minsong Cao and Ning Cao and Yun Liang and Kathy Miller",
year = "2011",
month = "12",
doi = "10.1007/s11307-010-0441-7",
language = "English",
volume = "13",
pages = "1183--1195",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT

AU - Stantz, Keith M.

AU - Cao, Minsong

AU - Cao, Ning

AU - Liang, Yun

AU - Miller, Kathy

PY - 2011/12

Y1 - 2011/12

N2 - Purpose: The purpose of this study was to quantify and model the longitudinal intra-tumor physiological response to a single dose of a monoclonal antibody specific to the VEGFR2 using dynamic contrast-enhanced CT. Material and Methods: Dynamic contrast-enhanced CT imaging was performed on athymic nude mice bearing xenograft VEGF-transfected MCF-7 tumors (MCF7 VEGF) to quantify intra-tumor physiology pre- and post-injection (days 2, 7, and 14) of a nonspecific (IgG1, controls) and specific (DC101, treated) monoclonal antibody targeting VEGFR2. Parametrical maps of tumor physiology-perfusion (F), permeability surface area (PS), fractional plasma (f p), and interstitial space (f is)-were obtained at four time points over a 2-week period. Results: A temporal multistage recovery process whereby a decoupling of the fractional change in physiological parameters (f p, F) was observed when comparing treated to control tumors: f p and perfusion decreased by a combined 27% (P<0.01) and 65% (P<0.01) on day 2, while only perfusion remained reduced by 46% (P<0.01) on day 7. Intra-tumor heterogeneity defined by the change in variance of perfusion decreased on days 2 and 7; no change in the variance of f p was observed. Analysis based on a mathematical model linking perfusion and vascular morphology indicates that a decrease in f p and perfusion was consistent with a reduction in blood vessel radius, followed by an increase in the vascular radius and tortuosity resulting in the decoupling of f p and perfusion before returning to control levels. Conclusion: Inhibiting VEGFR2 activity results in a temporal decoupling of physiological parameters, which can be explained by a combination of morphological changes influencing perfusion. Such a decoupling has the potential to significantly impact the delivery of pharmaceuticals and oxygen within solid tumors, critical factors in combined anti-angiogenic and radio- and chemotherapies.

AB - Purpose: The purpose of this study was to quantify and model the longitudinal intra-tumor physiological response to a single dose of a monoclonal antibody specific to the VEGFR2 using dynamic contrast-enhanced CT. Material and Methods: Dynamic contrast-enhanced CT imaging was performed on athymic nude mice bearing xenograft VEGF-transfected MCF-7 tumors (MCF7 VEGF) to quantify intra-tumor physiology pre- and post-injection (days 2, 7, and 14) of a nonspecific (IgG1, controls) and specific (DC101, treated) monoclonal antibody targeting VEGFR2. Parametrical maps of tumor physiology-perfusion (F), permeability surface area (PS), fractional plasma (f p), and interstitial space (f is)-were obtained at four time points over a 2-week period. Results: A temporal multistage recovery process whereby a decoupling of the fractional change in physiological parameters (f p, F) was observed when comparing treated to control tumors: f p and perfusion decreased by a combined 27% (P<0.01) and 65% (P<0.01) on day 2, while only perfusion remained reduced by 46% (P<0.01) on day 7. Intra-tumor heterogeneity defined by the change in variance of perfusion decreased on days 2 and 7; no change in the variance of f p was observed. Analysis based on a mathematical model linking perfusion and vascular morphology indicates that a decrease in f p and perfusion was consistent with a reduction in blood vessel radius, followed by an increase in the vascular radius and tortuosity resulting in the decoupling of f p and perfusion before returning to control levels. Conclusion: Inhibiting VEGFR2 activity results in a temporal decoupling of physiological parameters, which can be explained by a combination of morphological changes influencing perfusion. Such a decoupling has the potential to significantly impact the delivery of pharmaceuticals and oxygen within solid tumors, critical factors in combined anti-angiogenic and radio- and chemotherapies.

KW - DC101

KW - DCE-CT

KW - Fractional plasma volume

KW - Heterogeneity

KW - Perfusion

UR - http://www.scopus.com/inward/record.url?scp=84055167358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055167358&partnerID=8YFLogxK

U2 - 10.1007/s11307-010-0441-7

DO - 10.1007/s11307-010-0441-7

M3 - Article

C2 - 20957443

AN - SCOPUS:84055167358

VL - 13

SP - 1183

EP - 1195

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 6

ER -